Combination therapy to checkmate Glioblastoma: clinical challenges and advances. Issue 1 (16th October 2018)

• Record Type: Journal Article
• Authors: Ghosh, Debarati; Nandi, Saikat; Bhattacharjee, Sonali
• Is Part Of: Clinical and translational medicine. Volume 7:Issue 1(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-10-16
• Subjects: Combination therapy -- Glioblastoma multiforme -- Glioblastoma stem cells -- Targeted cancer therapy -- Tumor microenvironment -- Precision medicine -- Chemotherapy -- Tumor heterogeneity -- Drug resistance -- Radiotherapy -- Immunotherapy -- Clinical trials; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1186/s40169-018-0211-8
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: Combination therapy is increasingly becoming the cornerstone of current day antitumor therapy. Glioblastoma multiforme is an aggressive brain tumor with a dismal median survival post diagnosis and a high rate of disease recurrence. The poor prognosis can be attributed to unique treatment limitations, which include the infiltrative nature of tumor cells, failure of anti‐glioma drugs to cross the blood–brain barrier, tumor heterogeneity and the highly metastatic and angiogenic nature of the tumor making cells resistant to chemotherapy. Combination therapy approach is being developed against glioblastoma with new innovative combination drug regimens being tested in preclinical and clinical trials. In this review, we discuss the pathophysiology of glioblastoma, diagnostic markers, therapeutic targeting strategies, current treatment limitations, novel combination therapies in the context of current treatment options and the ongoing clinical trials for glioblastoma therapy.